Last reviewed · How we verify
NCT06977139: INSTYLE
Interventional Structural Registry - LuEbeck
trial in Structural Heart Disease in 2,000 participants. Currently enrolling.
1 January 2030
Quick facts
| Lead sponsor | Prof. Dr. med. Ingo Eitel |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 11 September 2021 |
| Primary completion | 1 January 2030 |
| Estimated completion | 1 January 2035 |
| Sites | 1 location across Germany |
Conditions studied
- Structural Heart Disease — all drugs for Structural Heart Disease →
Sponsor
Prof. Dr. med. Ingo Eitel
Who can join
18 and older, any sex, with Structural Heart Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the registry is to investigate the effect of catheter-assisted procedures in the context of structural heart disease on clinical morbidity and mortality. Furthermore, the long-term prognosis of patients after a catheter-based procedure is to be evaluated. In particular, the following parameters will be documented and the following questions discussed: * Underlying and concomitant diseases of these patients * Evaluation of the methods in relation to the respective disease * Safety - acute and long-term * Effectiveness - periprocedural, hospital and long-term course * Concomitant therapies
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06977139
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Structural Heart Disease
Currently open trials in the same condition.
- NCT07112391 — Pressure-Volume Loop Assessment in Valvular Heart Disease · recruiting
- NCT06937983 — Optimised Decrement Evoked Potential (DeEP) Mapping to Guide Ventricular Tachycardia (VT) Ablation in Patients With Stru · NA · recruiting
- NCT06783933 — Artificial Intelligence-assisted Diagnosis · active not recruiting
- NCT06001073 — Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics · recruiting
Other Prof. Dr. med. Ingo Eitel trials
Trials by the same sponsor.
- NCT06804161 — SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension · Phase 3 · recruiting
- NCT06804148 — MYVAL Transcatheter Heart Valve System - Prospective German Multicenter Registry · recruiting
- NCT05204212 — Left Atrial Appendage Closure in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic KIDNEY Disease · NA · recruiting
- NCT04301921 — Strategies to Maintain Radial Artery Patency Following Diagnostic Coronary Angiography - Diagnostic Transradial Coronary · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06977139 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prof. Dr. med. Ingo Eitel
- Last refreshed: 18 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06977139.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing